Nirsevimab continued to provide strong protection against respiratory syncytial virus-associated bronchiolitis in paediatric ...
Regardless of blood eosinophil count threshold, adults with COPD and an eosinophilic phenotype experienced significantly fewer moderate/severe exacerbations in a year with mepolizumab vs. placebo, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback